13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
73 檔
32.8%
In Q1 2026, Birchview Capital, LP's U.S. equity holdings reached a combined market value of $213.8M, distributed across 73 disclosed stock positions.
Birchview Capital, LP executed strategic sector rebalancing during Q1 2026, establishing 17 new positions while fully exiting 12 holdings and trimming 21 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KLAC | Kla CORP | Stock-Tech | 16.67% | +8.51% | -9.14% | |
| 2 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 10.57% | -2.56% | +1.13% | |
| 3 | CMPX | Compass Therapeutics Inc | Stock-Other | 4.41% | -2.69% | -7.98% | |
| 4 | LRCX | Lam Research CORP | Stock-Tech | 4.38% | +2.71% | -10.73% | |
| 5 | STOK | Stoke Therapeutics Inc | Stock-Other | 3.89% | -1.16% | -19.23% | |
| 6 | OVV | Ovintiv Inc | Stock-Energy | 3.63% | -0.98% | — | |
| 7 | NTLA | Intellia Therapeutics Inc | Stock-Other | 3.25% | -0.08% | +41.22% | |
| 8 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.74% | -2.14% | +11.11% | |
| 9 | SLDB | Solid Biosciences Inc | Stock-Other | 2.57% | +0.54% | -11.33% | |
| 10 | PRTA | Prothena Corporation plc | Stock-Other | 2.48% | -0.42% | +1.81% | |
| 11 | ✓ | Biodesix Inc | Stock-Other | 2.37% | +0.65% | — | |
| 12 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.17% | -0.15% | — | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.10% | -0.09% | -36.36% | |
| 14 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.04% | +0.10% | — | |
| 15 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.86% | -0.70% | -18.59% | |
| 16 | RLMD | Relmada Therapeutics Inc | Stock-Other | 1.62% | -0.30% | — | |
| 17 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.54% | -1.45% | — | |
| 18 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.52% | -0.38% | +50.00% | |
| 19 | NKTR | Nektar Therapeutics | Stock-Other | 1.27% | +1.37% | — | |
| 20 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.27% | -0.05% | — | |
| 21 | NVCR | NovoCure Limited | Stock-Healthcare | 1.26% | -1.26% | EXIT | |
| 22 | EQT | Eqt CORP | Stock-Energy | 1.25% | -0.39% | — | |
| 23 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.23% | -0.95% | — | |
| 24 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.22% | -0.60% | +0.19% | |
| 25 | CMPS | Compass Pathways PLC | Stock-Other | 1.18% | -0.98% | — | |
| 26 | PACB | Pacific Biosciences Of Calif | Stock-Other | 1.13% | -0.07% | +200.00% | |
| 27 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.13% | +0.07% | — | |
| 28 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.08% | +1.25% | -29.76% | |
| 29 | VERA | Vera Therapeutics Inc | Stock-Other | 1.01% | +0.15% | — | |
| 30 | ALKS | Alkermes plc | Stock-Healthcare | 1.01% | +0.22% | — | |
| 31 | ✓ | Engene Holdings Inc | Stock-Other | 0.97% | -0.97% | EXIT | |
| 32 | QURE | uniQure N.V. | Stock-Other | 0.94% | +0.15% | +227.06% | |
| 33 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.78% | +0.33% | — | |
| 34 | QDELUSD | Quidelortho CORP | Stock-Other | 0.77% | -0.04% | +13.78% | |
| 35 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.77% | -0.13% | — | |
| 36 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.74% | -0.74% | EXIT | |
| 37 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.70% | -0.11% | — | |
| 38 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.65% | -0.65% | EXIT | |
| 39 | IMNM | Immunome Inc | Stock-Other | 0.62% | -0.12% | -61.54% | |
| 40 | FCX | Freeport-mcmoran Inc | Stock-Materials | 0.60% | -0.07% | -0.03% | |
| 41 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.58% | +0.11% | -1.01% | |
| 42 | BIIB | Biogen Inc | Stock-Healthcare | 0.52% | +0.39% | — | |
| 43 | LPCN | Lipocine Inc | Stock-Other | 0.51% | -0.49% | — | |
| 44 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.49% | +0.28% | -32.09% | |
| 45 | HROW | Harrow Inc | Stock-Other | 0.48% | — | -29.41% | |
| 46 | PHVS | Pharvaris N.V. | Stock-Other | 0.48% | — | — | |
| 47 | VSTM | Verastem Inc | Stock-Other | 0.45% | -0.45% | EXIT | |
| 48 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.43% | -0.43% | EXIT | |
| 49 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.37% | +0.85% | — | |
| 50 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.37% | -0.07% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NTLA | Intellia Therapeutics Inc | +1.6% | +41.22% | Add |
| 2 | ✓ | Biodesix Inc | +1.2% | — | Unchanged |
| 3 | OVV | Ovintiv Inc | +1.2% | — | Unchanged |
| 4 | KLAC | Kla CORP | +1.1% | -9.14% | Trim |
| 5 | BMY | Bristol-myers Squibb Co | +1% | +1.13% | Add |
| 6 | UTHR | United Therapeutics CORP | +0.7% | +50.00% | Add |
| 7 | PACB | Pacific Biosciences Of Calif | +0.6% | +200.00% | Add |
| 8 | QURE | uniQure N.V. | +0.5% | +227.06% | Add |
| 9 | NKTR | Nektar Therapeutics | +0.5% | — | Unchanged |
| 10 | LRCX | Lam Research CORP | +0.3% | -10.73% | Trim |
| 11 | SLDB | Solid Biosciences Inc | +0.2% | -11.33% | Trim |
| 12 | ALKS | Alkermes plc | +0.2% | — | Unchanged |
| 13 | EQT | Eqt CORP | +0.2% | — | Unchanged |
| 14 | XENE | Xenon Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 15 | NVCR | NovoCure Limited | +0.1% | +33.02% | Add |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 17 | APLSUSD | Apellis Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 18 | FCX | Freeport-mcmoran Inc | +0.1% | -0.03% | Trim |
| 19 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 20 | PRTA | Prothena Corporation plc | 0% | +1.81% | Add |
| 21 | CYTK | Cytokinetics Inc | 0% | — | Unchanged |
| 22 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | +2.96% | Add |
| 23 | OMGBP | Outset Medical Inc | 0% | -0.03% | Trim |
| 24 | PHVS | Pharvaris N.V. | — | — | Unchanged |
| 25 | TRIN | Trinity Capital Inc | — | — | Unchanged |
| 26 | KBDC | Kayne Anderson Bdc Inc | 0% | — | Unchanged |
| 27 | ELUT | Elutia Inc | 0% | -37.23% | Trim |
| 28 | VYGR | Voyager Therapeutics Inc | 0% | — | Unchanged |
| 29 | BBIO | Bridgebio Pharma Inc | 0% | — | Unchanged |
| 30 | DCGO | Docgo Inc | 0% | -20.71% | Trim |
| 31 | CADL | Candel Therapeutics Inc | 0% | — | Unchanged |
| 32 | HALO | Halozyme Therapeutics Inc | 0% | — | Unchanged |
| 33 | AXSM | Axsome Therapeutics Inc | -0.1% | -1.01% | Trim |
| 34 | RARE | Ultragenyx Pharmaceutical In | -0.1% | — | Unchanged |
| 35 | FHTX | Foghorn Therapeutics Inc | -0.1% | — | Unchanged |
| 36 | LUNG | Pulmonx CORP | -0.1% | -0.14% | Trim |
| 37 | NBIX | Neurocrine Biosciences Inc | -0.2% | — | Unchanged |
| 38 | VSTM | Verastem Inc | -0.2% | — | Unchanged |
| 39 | GOSS | Gossamer Bio Inc | -0.3% | -86.85% | Trim |
| 40 | APGE | Apogee Therapeutics Inc | -0.3% | -43.75% | Trim |
| 41 | VERA | Vera Therapeutics Inc | -0.3% | — | Unchanged |
| 42 | CORT | Corcept Therapeutics Inc | -0.3% | -29.76% | Trim |
| 43 | QDELUSD | Quidelortho CORP | -0.4% | +13.78% | Add |
| 44 | TVTX | Travere Therapeutics Inc | -0.5% | -32.09% | Trim |
| 45 | HROW | Harrow Inc | -0.5% | -29.41% | Trim |
| 46 | ACAD | Acadia Pharmaceuticals Inc | -0.5% | — | Unchanged |
| 47 | CMPX | Compass Therapeutics Inc | -0.6% | -7.98% | Trim |
| 48 | PHAT | Phathom Pharmaceuticals Inc | -0.7% | — | Unchanged |
| 49 | BCYC | Bicycle Therapeutics Plc-adr | -0.7% | +0.19% | Add |
| 50 | PTGX | Protagonist Therapeutics Inc | -0.7% | -36.36% | Trim |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 73 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KLAC, BMY, CMPX) accounted for 32.8% of total reported equity market value during Q1 2026.
Top New Position Initiated
RLMD
市值: $2.8M
Top Position Liquidated / Trimmed
AM6
前期市值: $3.6M
During Q1 2026, Birchview Capital, LP's top holdings by market value included KLAC (16.7%)、BMY (10.6%)、CMPX (4.4%). The largest single position, KLAC, represented 16.7% of total portfolio value.
In Q1 2026, Birchview Capital, LP made 61 total portfolio adjustments, initiating 17 new buys, adding to 11 positions, trimming 21 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.